Shares of ProNAi Therapeutics Inc. (NASDAQ:DNAI) have been given an average broker rating score of 2.50 (Hold) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company.
Analysts have set a 12-month consensus price objective of $2.50 for the company and are forecasting that the company will post ($0.30) EPS for the current quarter, according to Zacks. Zacks has also given ProNAi Therapeutics an industry rank of 91 out of 265 based on the ratings given to related companies.
Several equities research analysts recently weighed in on DNAI shares. Wedbush restated an “outperform” rating and set a $36.00 price target on shares of ProNAi Therapeutics in a research report on Friday, May 27th. Jefferies Group restated a “buy” rating on shares of ProNAi Therapeutics in a research report on Sunday, May 29th. SunTrust Banks Inc. lowered ProNAi Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the company from $25.00 to $4.00 in a research report on Monday, June 6th. Finally, Zacks Investment Research lowered ProNAi Therapeutics from a “buy” rating to a “sell” rating in a research report on Monday, August 8th.
ProNAi Therapeutics (NASDAQ:DNAI) opened at 1.88 on Tuesday. ProNAi Therapeutics has a 12 month low of $1.77 and a 12 month high of $29.14. The stock’s 50 day moving average price is $1.89 and its 200-day moving average price is $3.84. The firm’s market capitalization is $57.01 million.
ProNAi Therapeutics (NASDAQ:DNAI) last released its quarterly earnings results on Friday, August 12th. The company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by $0.05. Equities analysts anticipate that ProNAi Therapeutics will post ($1.32) EPS for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. A.R.T. Advisors LLC boosted its position in shares of ProNAi Therapeutics by 35.3% in the first quarter. A.R.T. Advisors LLC now owns 16,100 shares of the company’s stock worth $108,000 after buying an additional 4,200 shares during the last quarter. Bridgeway Capital Management Inc. bought a new position in shares of ProNAi Therapeutics during the second quarter worth about $109,000. Ancora Advisors LLC bought a new position in shares of ProNAi Therapeutics during the second quarter worth about $132,000. Panagora Asset Management Inc. bought a new position in shares of ProNAi Therapeutics during the second quarter worth about $168,000. Finally, Minerva Advisors LLC bought a new position in shares of ProNAi Therapeutics during the second quarter worth about $227,000. Institutional investors and hedge funds own 35.25% of the company’s stock.
ProNAi Therapeutics Company Profile
ProNAi Therapeutics, Inc is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.